Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence†

被引：0
|
作者：
Jennifer S. Orman
Gillian M. Keating
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
CNS Drugs | 2009年 / 23卷
关键词：
Clonidine; Naloxone; Buprenorphine; Withdrawal Syndrome; Opioid Antagonist;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Buprenorphine/naloxone (Suboxone®) comprises the partial μ-opioid receptor agonist buprenorphine in combination with the opioid antagonist naloxone in a 4: 1 ratio. When buprenorphine/naloxone is taken sublingually as prescribed, the naloxone exerts no clinically significant effect, leaving the opioid agonist effects of buprenorphine to predominate. However, when buprenorphine/naloxone is parenterally administered in patients physically dependent on full agonist opioids, the opioid antagonism of naloxone causes withdrawal effects, thus reducing the abuse potential of the drug combination.
引用
收藏
页码：899 / 902
页数：3
相关论文
共 50 条
  • [31] Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence
    Fiellin, David A.
    Pantalon, Michael V.
    Chawarski, Marek C.
    Moore, Brent A.
    Sullivan, Lynn E.
    O'Connor, Patrick G.
    Schottenfeld, Richard S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (04): : 365 - 374
  • [32] Treatment of Kratom Dependence With Buprenorphine-Naloxone Maintenance
    Buresh, Megan
    JOURNAL OF ADDICTION MEDICINE, 2018, 12 (06) : 481 - 483
  • [33] Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth
    Warden, Diane
    Subramaniam, Geetha A.
    Carmody, Thomas
    Woody, George E.
    Minhajuddin, Abu
    Poole, Sabrina A.
    Potter, Jennifer
    Fishman, Marc
    Bogenschutz, Michael
    Patkar, Ashwin
    Trivedi, Madhukar H.
    ADDICTIVE BEHAVIORS, 2012, 37 (09) : 1046 - 1053
  • [34] Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine
    Chhabra, Neeraj
    Aks, Steven E.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2020, 38 (03): : 691.e3 - 691.e4
  • [35] Buprenorphine/Naloxone Treatment Outcomes for Opioid-Dependent Youth
    Van Hook, Shari
    Kuzubova, K.
    Sherritt, L.
    Sanchez-Samper, X.
    Levy, S.
    Harris, S. K.
    SUBSTANCE ABUSE, 2014, 35 (02) : 205 - 205
  • [36] Induction and switch to buprenorphine-naloxone in opioid dependence treatment: Predictive value of the first four weeks
    Apelt, Sabine M.
    Scherbaum, Norbert
    Soyka, Michael
    HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2014, 16 (03) : 87 - 97
  • [37] Buprenorphine/naloxone sublingual tablet (Zubsolv®): A guide to its use in the maintenance treatment of opioid dependence in the USA
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2013, 29 (11) : 336 - 341
  • [38] Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence
    Ghosh, Abhishek
    Mahintamani, Tathagata
    Rana, Devender K.
    Basu, Debasish
    Mattoo, Surendra K.
    INDIAN JOURNAL OF PSYCHIATRY, 2022, 64 (02) : 199 - +
  • [39] Buprenorphine-naloxone use in pregnancy for treatment of opioid dependence Retrospective cohort study of 30 patients
    Dooley, Joe
    Gerber-Finn, Lianne
    Antone, Irwin
    Guilfoyle, John
    Blakelock, Brittany
    Balfour-Boehm, Jazmyn
    Hopman, Wilma M.
    Jumah, Naana
    Kelly, Len
    CANADIAN FAMILY PHYSICIAN, 2016, 62 (04) : E194 - E200
  • [40] Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder
    Nosyk, Bohdan
    Min, Jeong Eun
    Homayra, Fahmida
    Kurz, Megan
    Guerra-Alejos, Brenda Carolina
    Yan, Ruyu
    Piske, Micah
    Seaman, Shaun R.
    Bach, Paxton
    Greenland, Sander
    Karim, Mohammad Ehsanul
    Siebert, Uwe
    Bruneau, Julie
    Gustafson, Paul
    Kampman, Kyle
    Korthuis, P. Todd
    Loughin, Thomas
    Mccandless, Lawrence C.
    Platt, Robert W.
    Schnepel, Kevin T.
    Socias, M. Eugenia
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (21): : 1822 - 1831
12345